t
| TIDM | AMS |
| Share Price | 280.50p-0.53% |
| Market Cap | £615.99m |
Advanced Medical Solutions Group plc (AMS) issued a notification on 6 March 2026 concerning its existing block admission arrangements for six employee and executive share schemes. For the period from 6 September 2025 to 5 March 2026, a total of 1,424,268 securities were issued or allotted under these schemes. The block schemes were also increased by 10,400,000 securities since the last return.
| Date | 6 Mar 2026 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 5616V |
|
|
6 March 2026 |
("AMS", the "Company" or the "Group")
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
|
Name of applicant: |
Advanced Medical Solutions Group plc |
|||
|
Name of scheme: |
Block Scheme for: 1. Employee Share Purchase Plan 2. Group Share Option Plan 3. Company Share Option Plan 4. Unapproved Executive Share Option Scheme 5. Long Term Incentive Plan 6. Deferred Annual Bonus Scheme |
|||
|
Period of return: |
From: |
6 September 2025 |
To: |
5 March 2026 |
|
Balance of unallotted securities under scheme(s) from previous return: |
1. Nil 2. Nil 3. 87,573 4. 84,541 5. Nil 6. 229,762 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
1. 2,000,000 2. 4,000,000 3. 200,000 4. 200,000 5. 4,000,000 6. Nil |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period: |
1. 563,881 2. 20,481 3. 32,502 4. 37,057 5. 758,428 6. 11,919 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
1. 1,436,119 2. 3,979,519 3. 255,071 4. 247,484 5. 3,241,572 6. 217,843 |
|||
|
Number and class of securities originally listed and the date of admission: |
(i) 4,476,264 ordinary shares of 5p each admitted on 6 September 2018. (ii) 10,400,000 ordinary share of 5p each admitted on 15 September 2025. |
|||
|
Name of contact: |
Owen Bromley |
|
Telephone number of contact: |
01606 545514 |
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
|
|
|
Optimum Strategic Communications |
Tel: +44 (0) 20 4566 8543 |
|
Mary Clark / Nick Bastin / Isabelle Abdou |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence / David Anderson |
|
|
|
|
|
Berenberg (Joint Broker) |
Tel: +44 (0) 20 3207 7800 |
|
Toby Flaux / Detlir Elezi |
|
|
|
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is an innovative tissue healing medical device company delivering high-performing solutions that match or surpass market leaders, clinically, technically, and commercially. From adhesives and sealants, to biosurgical devices and sutures, AMS's products offer superior usability, quality and design. AMS's strength lies in combining advanced material science with applicator device design and development, in collaboration with surgeons and Key Opinion Leaders, creating differentiated devices that improve patient outcomes without compromising quality or affordability.
AMS's scalable, resilient business model is built on disciplined execution, portfolio focus, and capital efficiency. Its diversified product and geographic mix mitigates volatility, ensuring consistent performance even when individual segments fluctuate. Following its acquisition of Peters Surgical, AMS is unlocking operational and commercial synergies, accelerating its U.S. and international expansion, and increasing the percentage of sales made through its direct sales teams. With surgical products driving the lion's share of group revenues and a clear top-line trajectory, AMS is positioned for scalable growth, margin improvement, and long-term value creation.